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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

THE INCLUSION OF PREGNANT WOMEN
IN CLINICAL RESEARCH
BARBARA A. NOAH*
ABSTRACT: THE INCLUSION OF PREGNANT WOMEN IN CLINICAL RESEARCH
In the past three decades, there has been unprecedented growth in
medical research utilizing human subjects, with much promise for new
treatments that extend life, improve quality of life, and prevent disease and
disability. Safe prescribing of drug therapies requires that researchers design
clinical trials to test products for the benefit of all persons who are likely to
utilize them, not just a limited population. For this reason, it is essential that
clinical trials include women, pregnant women, children, and racial
minorities, as appropriate, because these populations sometimes exhibit
different patterns of response or adverse reactions.
Despite some significant progress in including women in clinical
research, there is a dearth of sound research data on the safety and efficacy
of already approved and commonly used medications for pregnant women.
At this point, nearly all medications used to treat illness in pregnant women,
including common chronic conditions such as hypertension, depression,
diabetes, epilepsy, and cancer, are used off-label; that is, outside of the
FDA-approved uses based on clinical trial and post-marketing data.
Physicians must make prescribing decisions for their pregnant patients
without the benefit of randomized, controlled clinical trials testing the safety
and efficacy of drugs in pregnant women or the impact of these products on
the health of the fetus. This problem of prescribing in the dark is receiving
some attention in the medical and scientific community, but progress
appears slow. Meanwhile, pregnant women face the difficult choice between
taking untested drugs or foregoing necessary pharmacotherapy during
pregnancy, potentially to the detriment of both woman and fetus.
The default position — to exclude pregnant women from clinical
research — is untenable. Although serious challenges in study design,
institutional review board (IRB) oversight, and research participant safety
make the thought of research in pregnant women daunting, it is important to
* Barbara A. Noah, Professor of Law, Western New England University School of Law. J.D.,
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find ways to test commonly used drugs in pregnant patients. Postponing
action until consensus on the ethical and regulatory issues can be achieved
is no solution. Women get ill while pregnant or become pregnant while
suffering from chronic illness, and therefore must sometimes take
prescription and non-prescription medications. Researchers must, therefore,
design and implement clinical trials and other types of data collection
techniques for both new and already-approved drugs and therapies that will
generate data for the safe use of these drugs for pregnant women and their
fetuses. This article will describe the current status of inclusion of pregnant
women in research, and will discuss some of the FDA-related regulatory
barriers to collecting safety and efficacy information and approaches to
improve the availability of data to support safe drug prescribing during
pregnancy. Finally, although pro-life constituencies have significant influence
on health policy, efforts to improve the quality and quantity of safety data
should not bow to external, non-science-based attempts at interference with
these goals.
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I. INTRODUCTION
In the past three decades, there has been substantial growth in medical
research utilizing human subjects, with much promise for new treatments
that extend life, improve quality of life, and prevent disease and disability.
Safe prescribing of drug therapies requires that researchers design clinical
trials to test products for the benefit of all persons who are likely to utilize
them, not just a limited population. For this reason, it is essential that
clinical trials include all sub-populations who may utilize a particular drug.
Although there has been good progress in the inclusion of women in clinical
research,1 the challenges of studying the safety of drugs in pregnant women
has caused clinical research with this population to lag, leaving physicians
and patients with inadequate data on which to base prescribing decisions.
Various stakeholders have acknowledged the problem,2 but progress
appears slow.
For the past two decades, the government and the clinical research
community have taken significant steps to include women, racial minorities,
and children in clinical research in recognition of the fact that prescription
drugs function differently and pose different risks among sub-populations.3
But it is only more recently that the question of how best to gather data on
the safety of prescription drugs and other substances in pregnancy has
1. See Jesse A. Berlin & Susan S. Ellenberg, Inclusion of Women in Clinical Trials, 7
BMC MED. 56 (2009) (describing the variety of approaches used during the 1980s and 1990s
to encourage equity for women in clinical research).
2. See, e.g., NIH Looks to Increase Enrollment of Pregnant Women, GUIDE TO GOOD
CLINICAL PRACTICE NEWSLETTER, Feb. 1, 2011, available at http://fda.complianceexpert.com/
news/nih-looks-to-increase-enrollment-of-pregnant-women-1.93029?qr=1; Mary A. Foulkes
et al., Clinical Research Enrolling Pregnant Women: A Workshop Summary, 20 J. WOMEN’S
HEALTH 1429, 1429 (2011).
3. The latest data demonstrate that women now make up the majority of clinical trial
participants. In NIH-funded research, women now comprise over 63% of study participants.
See OFFICE OF WOMEN’S HEALTH, FOOD & DRUG ADMIN., DIALOGUES ON DIVERSIFYING CLINICAL
TRIALS 9 (2011), available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/
WomensHealthResearch/UCM334959.pdf. See also U.S. GOV’T ACCOUNTABILITY OFFICE,
GAO-01-754, WOMEN’S HEALTH: WOMEN SUFFICIENTLY REPRESENTED IN NEW DRUG TESTING,
BUT FDA OVERSIGHT NEEDS IMPROVEMENT (2001), available at http://www.gao.gov/new.items/
d01754.pdf. Regulatory bodies have made similar efforts, with less success, to promote the
inclusion of children and racial minorities in clinical research. See, e.g., Barbara A. Noah, Just
a Spoonful of Sugar: Drug Safety for Pediatric Populations, 37 J.L. MED. & ETHICS 280, 280
(2009) [hereinafter Noah, Spoonful of Sugar]; Barbara A. Noah, The Participation of
Underrepresented Minorities in Clinical Research, 29 AM. J.L. & MED. 221, 224 (2003)
[hereinafter Noah, Underrepresented Minorities]. There is a related need for better training for
physicians about sex-based differences in adverse drug reactions and sex-based
recommendations for dosages. See Editorial: Putting Gender on the Agenda, 465 NATURE
665, 665 (2010).
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received more direct attention; pregnant women are the last “orphaned”
population in clinical research. The Second Wave Initiative, founded in
2009, is a collaborative organization of academics who are working to
promote scientific and ethically sound research efforts in order to improve
healthcare for pregnant women.4 The topic is also receiving much needed
attention from other quarters, including the Office of Research on Women’s
Health, part of the Department of Health and Human Services (HHS), which
recently published proceedings from a research forum on the issues.5 The
Institute of Medicine’s Committee on Ethical and Legal Issues Relating to the
Inclusion of Women in Clinical Research also has taken the position that
pregnant women be “presumed eligible” to participate in clinical trials,6 a
position that is very much the reverse of the current presumption against
inclusion. All of this attention and action is significant but, unless the
research community can address and overcome the predominant fear of
injury to the fetus, progress will remain slow.
Pregnant women and their fetuses deserve healthcare, including
prescription medications, that is based on sound scientific evidence of safety
and efficacy.7 Women of childbearing age suffer from a number of common
conditions that require prescription medication for treatment, yet do not
preclude pregnancy.8 Women with chronic illnesses become pregnant, and
pregnant women develop illnesses. The use of prescription drugs during
pregnancy is therefore unavoidable, or at least medically appropriate at
times. There is, however, a marked absence of sound research data on the
safety and efficacy of most Food and Drug Administration (FDA) approved

4. THE SECOND WAVE INITIATIVE, http://secondwaveinitiative.org (last visited Apr. 16,
2014).
5. See NATIONAL INSTITUTES OF HEALTH OFFICE OF RESEARCH ON WOMEN’S HEALTH,
INTRODUCTION TO ENROLLING PREGNANT WOMEN: ISSUES IN CLINICAL RESEARCH 7 (2010),
available at http://orwh.od.nih.gov/resources/policyreports/pdf/ORWH-EPW-Report
2010.pdf [hereinafter ORWH REPORT].
6. WOMEN AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES RELATING TO THE INCLUSION
OF WOMEN IN CLINICAL RESEARCH 17 (Anna C. Mastroianni et al. eds., 1994).
7. See Laurence B. McCullough et al., A Comprehensive Ethical Framework for
Responsibly Designing and Conducting Pharmacologic Research that Involves Pregnant
Women, 193 AM. J. OBSTETRICS & GYNECOLOGY 901, 902 (2005) (discussing the use of
psychopharmacologic drugs during pregnancy and noting that there is no objective evidence
to guide prescribing of these drugs).
8. See Anne Drapkin Lyerly et al., The Second Wave: Toward Responsible Inclusion of
Pregnant Women in Research, 1 INT. J. FEMINIST APPROACHES TO BIOETHICS 5, 6 (noting that
chronic diseases are common during pregnancy and include chronic hypertension, diabetes,
psychiatric illness, cancer, autoimmune disease, and others, along with pregnancy-related
conditions such as nausea and vomiting and preeclampsia).
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and commonly used medications for pregnant women.9 The ethical issues
that arise in designing sound scientific approaches to test drugs in pregnant
women are complex and risk assessment is difficult, but procrastination is
not going to make these challenges easier.
The physiological changes of pregnancy can affect how drugs are
processed and excreted by the body, yet pharmacokinetic studies of
approved drugs are rarely conducted in pregnant women.10 Pregnancy
alters both liver and kidney function in ways that can significantly impact a
drug’s effectiveness.11 At this point, nearly all medications used to treat
illness in pregnant women, including common chronic conditions such as
hypertension, depression, asthma, thyroid disease, diabetes, and epilepsy,
are prescribed without adequate evidence about their safety for mother and
fetus during pregnancy.12 For prescription medications approved in the
United States between 2000 and 2010, over 70% had no data on the risk
of teratogenic harm,13 and 98% had insufficient data on which to assess this
risk.14 Even for older drugs that have been on the market from 1980

9. There is a similar lack of data on the safety of drugs used in children and in preterm
infants, though this topic is outside the scope of this paper. See, e.g., Jonathan M. Davis
et al., The Need for Rigorous Evidence of Medication Use in Preterm Infants: Is it Time for a
Neonatal Rule?, 308 JAMA 1435, 1435 (2012); Noah, Spoonful of Sugar, supra note 3, at
280 (describing a similar problem with safety and efficacy data for pediatric populations and
recommending approaches to encourage clinical research with children).
10. See Sara F. Goldkind et al., Enrolling Pregnant Women in Research – Lessons from
the H1N1 Influenza Pandemic, 362 NEW ENG. J. MED. 2241, 2241 (2010).
11. See id. at 2242. See also M.A. Andrew et al., Amoxicillin Pharmacokinetics in
Pregnant Women: Modeling and Simulation of Dosage Strategies, 81 CLINICAL
PHARMACOLOGY & THERAPEUTICS 547, 547-56 (2007) (concluding that it may be impossible to
provide doses of amoxicillin to pregnant women that will produce clinically effective drug
levels in the blood because of altered renal function during pregnancy); Lyerly et al., supra
note 8, at 8 (describing changes in blood flow through the kidneys that may result in higher
metabolism of certain drugs and adding that changes in blood volume, sex hormones, and
liver enzymes all can change how a pregnant woman’s body processes drugs).
12. See Lyerly et al., supra note 8, at 7 (noting that only a dozen or so medications are
expressly approved by the FDA for use in pregnancy and that they are all medications
specifically related to pregnancy or childbirth related issues such as anesthesia, severe nausea
and vomiting, and induction of labor).
13. A teratogen is defined as “an agent that can produce a permanent abnormality of
structure or function in an organism exposed during embryonic or fetal life.” See Preamble,
Teratogen Information System (TERIS), UNIVERSITY OF WASHINGTON, available at
http://depts.washington.edu/terisweb/teris/Preamble.htm (last visited Apr. 16, 2014).
14. See Margaret P. Adam et al., Evolving Knowledge of the Teratogenicity of
Medications in Human Pregnancy, 157 AM. J. MED. GENETICS PART C (SEMINARS MED.
GENETICS) 175, 177 (2011) (reviewing the safety information available for the 172 drugs
approved during this ten year period).
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through 2000, it took an average of 27 years for sufficient data to be
gathered on which to characterize the risk of teratogenicity.15
Physicians, therefore, often must make prescribing decisions for their
pregnant patients without the benefit either of randomized, controlled
clinical trials or retrospective observational studies evaluating the safety and
efficacy of drugs in pregnant women or the impact of these products on the
health of the fetus. This lack of clinical safety and efficacy data regarding
prescription drugs for pregnant women creates a Catch-22 situation. In
addition to the risk of injury to the fetus, prescribing drugs without adequate
scientific evidence of safety and effectiveness in pregnancy risks inadequate
treatment of the mother’s medical condition and, of course, the mother’s
health may directly affect the health of the fetus. And, from an abundance of
caution, some pregnant women may simply avoid taking medically
necessary drugs during pregnancy, exposing themselves and the fetus to a
different but equally serious kind of risk.
The lack of adequate safety information for drugs in pregnancy creates
widespread risk because prescription and non-prescription drug use in
pregnancy is common. The latest available data from the Centers for
Disease Control and Prevention (CDC) show that nearly 90% of women take
at least one medication during pregnancy and that 70% take at least one
prescription medication.16 Moreover, in the past three decades, the use of
prescription medications during the first trimester of pregnancy has
increased by more than 60%.17 For example, data indicate that pregnant

15. See id. at 179 (evaluating the development of safety data on teratogenicity for drugs
approved between 1980 and 2000 and concluding that, for the 5% of drugs that actually
were assigned a pregnancy risk category, the “mean time for a treatment originally classified
as having an undetermined risk to be assigned a more precise risk” was 27 years). See also
W.Y. Lo & J.M. Friedman, Teratogenicity of Recently Introduced Medications in Human
Pregnancy, 100 OBSTETRICS & GYNECOLOGY 465, 468 (2002) (concluding that, as of 2002,
91.2 % of drugs introduced to the market between 1980 and 2000 still had an undetermined
risk of teratogenicity).
16. See Data and Statistics: Use of Medication in Pregnancy, CTRS. FOR DISEASE CONTROL,
available at http://www.cdc.gov/pregnancy/meds/data.html (last visited Apr. 16, 2014)
[hereinafter CDC Pregnancy Data]. See also Allen A. Mitchell et al., Medication Use during
Pregnancy with Particular Focus on Prescription Drugs: 1976 - 2008, 205 AM. J. OBSTETRICS &
GYNECOLOGY 51.e1, 51.e3 (2011) (analyzing data from more than 30,000 women and also
finding that the use of four or more medications more than tripled and that prescription
medication use was higher among more educated and older mothers and was highest among
non-Hispanic whites); Susan E. Andrade et al., Prescription Drug Use in Pregnancy, 191 AM. J.
OBSTETRICS & GYNECOLOGY 398, 400 (2004) (examining a prescription drug database and
concluding that, as of 2004, approximately 64% of pregnant women in the U.S. receive
prescriptions for one or more medications, not including prenatal vitamins).
17. See CDC Pregnancy Data, supra note 16.
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women regularly receive prescriptions for antibiotics during pregnancy.18
Prescriptions for opioids and nonopioid analgesics for the management of
pain during pregnancy have increased by 40% between 2001 and 2011.19
The use of over-the-counter medications is also common. Two studies that
examined the medication histories of over 10,000 mothers found that at
least 65% of women took acetaminophen during pregnancy, 18% took
ibuprofen, and 15% took pseudoephedrine.20 As for herbal supplements,
nearly 11% of women report using herbal products three months before or
during pregnancy.21
Antidepressant use during pregnancy has increased from 2.5% of
pregnant women in 1998 to 8.1% in 2005.22 Many (but not all) women
discontinue antidepressant use during pregnancy,23 because there are
indications of risk associated with these drugs for those who continue
therapy throughout pregnancy. Although a large retrospective study of births
in Nordic countries found no increased risk of stillbirth or infant mortality
associated with the use of selective serotonin reuptake inhibitors (SSRIs), a

18. See Krista S. Crider et al., Antibacterial Medication Use during Pregnancy and Risk of
Birth Defects: National Birth Defects Prevention Study, 163 ARCHIVES PEDIATRIC & ADOLESCENT
MED. 978, 979-80 (2009) (concluding that several commonly-prescribed classes of antibiotics
appeared safe for use in pregnancy and were not associated with increased prevalence of
birth defects but recommending additional study of sulfonamides and nitrofurantoins, which
are associated with increased birth defects including serious defects such as anencephaly and
hypoplastic left heart syndrome).
19. See Antoine Malek & D.R. Mattison, Drugs and Medicines in Pregnancy: the Placental
Disposition of Opioids, 12 CURRENT PHARMACEUTICAL BIOTECHNOLOGY 797, 797 (2011)
(adding that women also self-medicate during pregnancy with previously prescribed opioids).
20. See Martha M. Werler et al., Use of Over-the-Counter Medications During Pregnancy,
193 AM. J. OBSTETRICS & GYNECOLOGY 771, 772 (2005) (concluding that “[s]tudies that
examine specific over-the-counter medications in relation to specific birth defects are
necessary to better inform pregnant women about risks and safety”).
21. See Cheryl S. Broussard et al., Herbal Use before and during Pregnancy, 202 AM. J.
OBSTETRICS & GYNECOLOGY 443.e1-6, 443.e2 (2010) (recommending that physicians
educate their pregnant patients about the use of herbal products during pregnancy and inform
them that little is known of associated risks).
22. See Sura Alwan et al., Patterns of Antidepressant Medication Use among Pregnant
Women in a United States Population, 51 J. CLINICAL PHARMACOLOGY 264, 265-66, 269
(2011) (examining the use of antidepressant medications in over 6500 mothers from ten states
and recommending that healthcare providers “carefully assess and discuss the potential risks
and benefits of continuing treatment during pregnancy with each patient”).
23. See I. Petersen et al., Pregnancy as a Major Determinant for Discontinuation of
Antidepressants: An Analysis of Data from the Health Improvement Network, 72 J. CLINICAL
PSYCHIATRY 979, 982 (2011) (finding that only 10% of women taking antidepressants before
pregnancy were still taking the drugs at the start of the third trimester).
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common form of antidepressant medication,24 other studies indicate risk
associations between SSRI use and congenital anomalies.25 Another study
found an increased risk of neonatal withdrawal26 associated with the SSRI
paroxetine.27
A variety of factors appear to have contributed to the increased use of
medication during pregnancy. In the 1960s, after the thalidomide tragedy,
many pregnant women were reluctant to take any drug. Over time,
however, the increasing availability of drugs for various conditions and the
increased diagnosis of various medical conditions have led to more
prescribing of drugs in general and during pregnancy.28 Moreover, because
half of pregnancies are unplanned,29 and half of pregnancies go undetected
until the fourth week after conception,30 many women unknowingly take
medications before realizing that they are pregnant.
The cause of most birth defects is unknown, though studies suggest that
genetic factors such as chromosomal abnormalities and abnormalities of a
single gene or gene pair account for about 25% of all congenital
24. See Olof Stephansson et al., Selective Serotonin Reuptake Inhibitors during Pregnancy
and Risk of Stillbirth and Infant Mortality, 309 JAMA 48, 51 (2013) (finding a slightly higher
rate of stillbirths and neonatal deaths in women who used SSRIs, but concluding that
hospitalization for serious depression, smoking history, and advanced maternal age
accounted for these differences, which were negligible once adjustments for these variables
were taken into account).
25. See Carol Louik et al., First-Trimester Use of Selective Seratonin Reuptake Inhibitors
and the Risk of Birth Defects, 356 NEW ENG. J. MED. 2675, 2675 (2007) (finding that SSRIs as
a group posed no increased risk of anomalies, but concluding that certain drugs in the class
were associated with a small but measurable increased risk of specific defects, although the
overall increased risk was very small).
26. See Emilio J. Sanz et al., Selective Serotonin Reuptake Inhibitors in Pregnant Women
and Neonatal Withdrawal Syndrome: A Database Analysis, 365 LANCET 482, 482 (2005)
(explaining that neonatal withdrawal syndrome associated with SSRIs includes symptoms such
as convulsions, irritability, abnormal crying, and tremor).
27. Id. at 484 (examining data from a large international database of adverse drug
events and concluding that the data signals an increased risk: out of a total of 102 cases
during the studied period from 11 different countries of SSRI use associated with either
neonatal convulsions or withdrawal syndrome were identified, the drug paroxetine was the
most commonly reported SSRI associated with these problems, although there were also cases
associated with fluoxetine, sertraline, and citalopram).
28. See Jane E. Brody, Too Many Pills in Pregnancy, N.Y. TIMES, Feb. 25, 2013, available
at http://well.blogs.nytimes.com/2013/02/25/too-many-pills-in-pregnancy/ (providing the
example of conditions like depression, which is now commonly diagnosed and treated with
medication).
29. Stanley K. Henshaw, Unintended Pregnancy in the United States, 30 FAM. PLANNING
PERSP. 24, 29 (1998).
30. R. Louise Floyd et al., Alcohol Use Prior to Pregnancy Recognition, 17 AM. J.
PREVENTIVE. MED. 101, 101-07 (1999).
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anomalies,31 while environmental factors including maternal infections and
exposure to drugs or other chemical agents appear to cause approximately
10% of congenital abnormalities.32 The FDA estimates that less than 1% of
birth defects are caused by medications taken during pregnancy, but notes
that this estimate may be inaccurate because there is very little systematic
effort to gather data on the question:
About 4 percent (1/28) of babies are born each year with a major birth
defect or congenital malformation. The March of Dimes defines a major
birth defect as an abnormality of structure, function, or metabolism that
either is fatal or that is present at birth and results in physical or mental
disability. For the majority of major birth defects (about 65 percent), the
etiology is unknown. Chemically induced birth defects, including those
associated with drug exposure, probably account for less than 1 percent of
all birth defects; few drugs are proven human teratogens at clinical doses.
Of the thousands of drugs available, only about 20 drugs or groups of
drugs (most being anticonvulsants, antineoplastics, or retinoids) are
recognized as having an increased risk of developmental abnormalities
when used clinically in humans. However, since few drugs have been
systematically studied to identify their full range of possible teratogenic risks,
we cannot assume that current knowledge is complete. The identification of
a drug’s teratogenic potential is important because drug-induced adverse
fetal effects are potentially preventable.33

Although efforts to limit the impact of chromosomal and genetic
abnormalities are beginning to succeed with the advent of more accurate
and available prenatal testing, the impact of exposures to potentially
teratogenic agents is also important because these exposures are often
preventable.
The FDA’s passive approach to collecting safety data on alreadylicensed drugs exacerbates the problem of inadequate drug safety data for
pregnant women and fetuses. The FDA regulations require only that
manufacturers of approved prescription drugs collect and forward to the
agency adverse drug reaction reports (including reports of suspected harm
to a pregnant women or her fetus) through a voluntary system of adverse
event reporting called MedWatch.34 Although some data about adverse

31. See Robert L. Brent & David A. Beckman, Environmental Teratogens, 66 BULL. N.Y.
ACAD. MED. 123, 125 tbl.1, 151(1990).
32. See id.
33. FOOD & DRUG ADMIN., REVIEWER GUIDANCE: EVALUATING THE RISKS OF DRUG EXPOSURE
IN HUMAN PREGNANCIES 2 (2005), available at http://www.fda.gov/downloads/sciencere
search/specialtopics/womenshealthresearch/ucm133359.pdf.
34. See Postmarketing Reporting of Adverse Drug Experience, 21 C.F.R. § 314.80
(2012).
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events is better than none, the FDA’s “mandatory” reporting system is only
as effective as the extent of voluntary participation (through submission of
adverse event reports by healthcare providers and patients to manufacturers)
permits.35 It often takes a good deal of time for sporadic reports of isolated
adverse events to accumulate to the point that regulatory bodies or
physicians can conclude that a particular drug poses risks to pregnant
women or their fetuses.36 A more active approach to data gathering for this
population seems appropriate.
There are some systems currently in place to gather or assess safety data
about drugs that are already in use in pregnant women. For example, the
Teratogen Information System (TERIS) uses a process to attempt to quantify
the risk of birth defects associated with various drugs and chemicals.37 The
information is compiled into a database that is available for physicians to
consult, although the database is intended to guide decisions about whether
to continue or terminate a pregnancy after exposure to a potentially
teratogenic agent rather than as a guide for making prescribing decisions.38
Although the availability of information to assess post-exposure risk in
pregnant women is important, this information alone is insufficient to help
physicians make prescribing decisions because the list of agents that have
been assessed does not include all drugs prescribed to women of
childbearing age. The CDC’s Safer Medication Use in Pregnancy Initiative
also seeks to collect and transmit data on medication use in pregnancy.39
35. See Barbara A. Noah, Adverse Drug Reactions: Harnessing Experiential Data to
Promote Patient Welfare, 49 CATH. U.L. REV. 449, 468-84 (2000) (describing and critiquing
the FDA’s MedWatch system).
36. FOOD & DRUG ADMIN., supra notes 33, at 3.
37. Teratogen Information System and the On-line Version of Shepard’s Catalog of
Teratogentic Agents, UNIVERSITY OF WASHINGTON, http://depts.washington.edu/terisweb/teris/
(last visited Apr. 16, 2014).
38. See id. See also Preamble, Teratogen Information System (TERIS), UNIVERSITY OF
WASHINGTON, available at http://depts.washington.edu/terisweb/teris/Preamble.htm (last
visited Apr. 16, 2014) (explaining that the analysis of various listed agents in the TERIS
database “has been made on the basis of the reproducibility, consistency, and biological
plausibility of available clinical, epidemiological, and experimental data. Reproducibility is
judged by whether similar findings have been obtained in independent studies. Concordance
is considered to be particularly important if the studies are of different design and if the types
of anomalies observed in various studies are consistent. Effects seen in animal investigations
are weighed more heavily if the exposure is similar in dosage and route to that encountered
clinically and if the species tested are closely related to humans phylogenetically.”).
39. See Treating for Two: Safe Medication Use in Pregnancy Initiative, CTRS. FOR DISEASE
CONTROL, http://www.cdc.gov/ncbddd/birthdefects/documents/ncbddd_birth-defects_medica
tionuseonepager_cdcrole.pdf (describing the initiative activities including partnering with other
federal agencies such as the FDA to gather data, developing a process for systematic,
evidence-based review of medications used during pregnancy and “adverse fetal outcomes,”
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There are also pregnancy registries for certain drugs that are known or
suspected teratogens.40
The lack of sufficient and reliable safety information about prescription
and non-prescription drugs also has consequences for women who search
for answers on the internet. As of 2006, 50% of women consulted the
internet for health information,41 and that number has likely increased since
then. Yet a recent study demonstrates that internet sources about drug safety
during pregnancy contain substantial amounts of inaccurate and conflicting
information.42 The investigators identified several deficiencies with the web
sources, including lack of references from peer-reviewed literature,
conflicting information about the safety of individual drugs, and some of the
products listed as “safe” in fact are rated on TERIS as having a “none to
minimal” or “minimal” risk or as having an “undetermined” risk of harm to
the fetus.43 Just over half of the websites suggested that women consult with
a physician before stopping or beginning a medication during pregnancy,
and less than 40% of the sites instructed women to take medications only
when necessary.44
The FDA is in the process of adopting revised drug labeling regulations
to guide physicians in the prescribing of drugs for pregnant women. The
original rule divided prescription drugs into five categories: A, B, C, D, and
X to reflect different levels of knowledge about the pregnancy risks
associated with various drugs.45 These regulations require that all drugs
(except for those which are not systemically absorbed) must contain
information on the drug’s teratogenic and other effects on reproduction and
pregnancy. This information must include, when available, a description of
studies in humans with the drug and any available data on the drug’s effects
on later growth and development of the child.46 Pregnancy Category A
and publishing information related to medication use during pregnancy to educate healthcare
providers and the public).
40. See infra notes 126-29 and accompanying text.
41. See Emily E. Petersen et al., Prescription Medication Borrowing and Sharing among
Women of Reproductive Age, 17 J. WOMEN’S HEALTH 5 tbl.3 (2008).
42. Stacey L. Peters et al., Safe Lists for Medications in Pregnancy: Inadequate Evidence
Base and Inconsistent Guidance from Web-based Information, 2011, 22
PHARMACOEPIDEMIOLOGY & DRUG SAFETY 324, 325 (2013) (surveying 25 websites, including
pregnancy information sites, 3 medical sites, and 17 clinical practice sources, that provided
data about drug safety in pregnancy).
43. See id. at 325-26, 327 fig.1.
44. Id. at 325, 327 (arguing that these websites may provide false reassurance to women
about the safety of various medications).
45. See Labeling Requirements for Prescription Drugs and/or Insulin, 21 C.F.R. §
201.57(c)(9) (2013).
46. See id.
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refers to drugs for which adequate and well-controlled trials in pregnant
women have demonstrated no risk to the fetus in the first trimester (and there
is no evidence of risk later in the pregnancy).47 Pregnancy Category B refers
to drugs for which only animal studies have been conducted which
demonstrate no risk to the fetus.48 Category C applies to drugs for which
animal studies show an adverse effect on the fetus, there are no adequate
and well-controlled trials in humans, and the benefits of using the drug may
outweigh its risks.49 Category D includes those drugs for which there is
positive evidence of risk to the human fetus based on adverse event reports
or studies in humans, but the potential benefits of the drug may nevertheless
outweigh the risks in some women.50 Finally, Category X refers to drugs for
which the evidence in animals or humans demonstrates a risk of fetal
abnormalities and the risk of using the drug clearly outweighs any potential
benefit.51 This category approach to pregnancy risk labeling has been
roundly criticized because it fails to distinguish between the severity of
various possible adverse outcomes associated with different drugs and it
makes no distinction based on dose, route of administration, or timing of
the use of the drug during the pregnancy.52
The new proposed rule for pregnancy and lactation labeling which, as
of early 2011, is in the final writing and clearance process,53 alters this
approach in several important ways. The proposed rule abandons the letterbased pregnancy categories in favor of a unified label format with three
major components: a summary of risks, clinical considerations, and a data
section.54 The fetal risk summary begins with a one line conclusion that

47. 21 C.F.R. § 201.57(c)(9)((i)(A)(1) (2013).
48. 21 C.F.R. § 201.57(c)(9)((i)(A)(2) (2013).
49. 21 C.F.R. § 201.57(c)(9)((i)(A)(3) (2013).
50. See 21 C.F.R. § 201.57(c)(9)(i)(A)(4) (2013).
51. See 21 C.F.R. § 201.57(c)(9)(i)(A)(5) (2013).
52. See C.D. Chambers et al., Drug Safety in Pregnant Women and their Babies:
Ignorance Not Bliss, 83 CLINICAL PHARMACOLOGY & THERAPEUTICS 181, 182 (2008)
(comparing two pregnancy category D drugs, one of which causes staining of the infant’s
teeth, while the other is associated with a high frequency of major birth defects, including
spina bifida).
53. See Pregnancy and Lactation Labeling, FOOD & DRUG ADMIN. (Feb. 2, 2014,
11:46 AM), http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources
/Labeling/ucm093307.htm.
54. See Summary of Proposed Rule on Pregnancy and Lactation Labeling, FOOD & DRUG
ADMIN. (Feb. 2, 2014 11:33 AM), http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
DevelopmentResources/Labeling/ucm093310.htm. See also Content and Format of Labeling
for Human Prescription Drug and Biological Products; Requirements for Pregnancy and
Lactation Labeling, 73 Fed. Reg. 30831, 30838-39 (proposed May 29, 2008) (to be codified
at 21 C.F.R. pt. 201).
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describes the likelihood of four kinds of developmental abnormalities,
including structural anomalies, fetal and infant mortality, impaired
physiological function, and alterations to growth.55 The clinical
considerations section will cover three topics that physicians generally
discuss with pregnant women and women of childbearing age, including
inadvertent exposure to drugs early in pregnancy, prescribing decisions, and
available safety data.56 Although these changes to pregnancy labeling will
help to avoid confusion, the FDA’s requirements for providing information to
prescribers is only as useful as the information available on which to base
the risk assessment and clinical indications. Without better collection and
distillation of that data, physicians will often still have to make prescribing
decisions based on insufficient or entirely absent data.
This article will describe the current status of inclusion of pregnant
women in research, and will examine the strengths and weaknesses of the
current regulatory system for clinical trials with a view to identifying obstacles
to increased data collection on drug safety in pregnancy. The article will
then explore proposals to encourage the collection of rigorous evidence of
safety for drugs used during pregnancy.
II. CLINICAL RESEARCH: REGULATORY BACKGROUND
The medical community often assumes over-optimistically that clinical
research will yield additional scientific knowledge to the benefit of many
patients.57 In reality, the system of designing and regulating clinical research
is highly flawed.58 Although federal regulatory agencies and state health

55. See Summary of Proposed Rule on Pregnancy and Lactation Labeling, supra note 54
(adding that the risk summary must state whether the conclusions are based on human or
animal data). See also 73 Fed. Reg. at 30840.
56. See Summary of Proposed Rule on Pregnancy and Lactation Labeling, supra note 54.
See also 73 Fed. Reg. at 30843-44.
57. See Barbara A. Noah, Bioethical Malpractice: Risk and Responsibility in Human
Research, 7 J. HEALTH CARE L. & POL’Y 175, 196-206 (2004) (describing pressures on the
engine of biomedical research and inadequacies in the current system of clinical research
oversight that may put participants at risk and that sometimes interferes with the quality of
data); Roger N. Rosenberg, Translating Biomedical Research to the Bedside, 289 JAMA 1305,
1305 (2003) (questioning the “assumption that the recent exponential growth of scientific
information about disease . . . heralds a rapid move to improve human health”).
58. The United States Government Accountability Office (GAO) and the Department of
Health and Human Services (HHS) have sounded the alarm, issuing highly critical reports
about the ineffectiveness of IRBs. The HHS Office of the Inspector General (OIG) has issued a
series of reports that criticize the operation of IRBs and Office of Human Research Protection’s
supervision of human research more generally. The reports focused on several problems
endemic to IRB operations, such as overwhelming workload, lack of expertise, and conflicts of
interest that interfered with proper review of research protocols. See, e.g., DEPT. OF HEALTH &
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policy bodies have increased their scrutiny of research activities in recent
years,59 some risk to research participants is unavoidable.60
A.

The Basics of Clinical Trial Regulation61

Existing federal regulations delegate to IRBs the responsibility to
safeguard research subjects who participate in clinical trials of experimental
and approved therapies and in non-therapeutic trials designed to gain
generalizable scientific knowledge. In order to protect human research
subjects effectively, IRBs must use their combined expertise to assess the
scientific, ethical, and legal validity of every proposed research protocol and
must continue vigilant monitoring of ongoing approved protocols.62
HUMAN SERVS., OEI-01-97-00193, INSTITUTIONAL REVIEW BOARDS: A TIME FOR REFORM (1998);
U.S. GOV’T ACCOUNTABILITY OFFICE, GAO/HEHS-96-72, SCIENTIFIC RESEARCH: CONTINUED
VIGILANCE CRITICAL TO PROTECTING HUMAN SUBJECTS (1996). The Department followed up with
another report that analyzed the extent of implementation of its recommendations. See DEPT.
OF HEALTH & HUMAN SERVS., OEI-01-97-00197, PROTECTING HUMAN RESEARCH SUBJECTS:
STATUS OF RECOMMENDATIONS (2000) (concluding that IRBs had made little progress in
implementing the recommendations); U.S. GOV’T ACCOUNTABILITY OFFICE, HUMAN SUBJECTS
RESEARCH, UNDERCOVER TESTS SHOW THE INSTITUTIONAL REVIEW BOARD SYSTEM IS VULNERABLE TO
UNETHICAL MANIPULATION GAO-09-448T (2009) (identifying opportunities for fraud,
manipulation, and deceit of institutional review boards by companies seeking clinical research
approval).
59. See, e.g., Elisabeth Rosenthal, New York Seeks to Tighten Rules on Medical Research,
N.Y. TIMES, Sept. 27, 1996, at B4 (describing the case of a 19-year-old healthy student
volunteer at the University of Rochester who died during a study designed to measure the
effects of pollutants on the lungs). HHS’s Office for Human Research Protections (OHRP)
temporarily suspended research under the supervision of IRBs at more than a dozen research
institutions because of non-compliance with regulatory requirements. See Donald F. Phillips,
IRBs Search for Answers and Support during a Time of Institutional Change, 283 JAMA 729,
729 (2000). OHRP also regularly criticizes the conduct of specified trials. See Robert
Steinbrook, Trial Design and Patient Safety – The Debate Continues, 349 NEW ENG. J. MED.
629, 629 (2003).
60. HHS has issued an advance notice of proposed rulemaking requesting comment on
how current clinical research regulations can be “modernized and revised to be more
effective . . . [in protecting human subjects] . . . while facilitating valuable research and
reducing burden, delay, and ambiguity for investigators.” See Human Subjects Research
Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44512 (proposed Jul. 26, 2011) (to be
codified at 21 C.F.R. pts. 50, 56).
61. The regulatory description in this part is adapted from Barbara A. Noah, Bioethical
Malpractice: Risk and Responsibility in Human Research, 7 J. HEALTH CARE L. & POL’Y 175,
182-96 (2004).
62. Much of this background section on clinical trial regulation is also adapted from
Barbara A. Noah, Bioethical Malpractice: Risk and Responsibility in Human Research, 7 J.
HEALTH CARE L. & POL’Y 175 (2004) (providing a more detailed discussion of IRB policies and
practices).
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There are two sets of parallel federal regulations applicable to human
subjects research and these federal rules apply to most, though not all,
clinical research conducted in the United States. The FDA regulations apply
to all human subjects research involving products such as drugs, medical
devices, and biological products that eventually will support a licensing
application to the agency,63 while the HHS regulations cover all research
conducted or supported by the federal government.64 These two overlapping
sets of federal research regulations provide a wealth of detail about
standards for approval and supervision of human research. Nevertheless,
the regulations leave some of the most difficult scientific issues unresolved,
and they leave important ethical questions to the discretion of IRBs, which
may vary substantially in their interpretation and application of the
regulatory requirements.65
The regulations setting out criteria for approval require an IRB to assess
a variety of scientific and ethical factors. First, the study design must
minimize the risks to the subjects by using sound research procedures and,
in the case of therapeutic research, by preferring procedures that typically
would comprise standard diagnostic tests or treatment.66 In addition to
ensuring that risks to subjects are minimized, the IRB must evaluate whether
those risks, whatever their magnitude, are reasonable in relation to the
probable benefits to the subjects and the importance of the anticipated

63. See 21 C.F.R. § 50.1(a) (2013).
64. See 45 C.F.R. § 46.101(a) (2013). Many sections of the FDA and HHS regulations
are nearly identical. For a useful comparison between the two sets of regulations, see
Comparison of FDA and HHS Human Subject Protection Regulations, FOOD & DRUG ADMIN.,
http://www.fda.gov/oc/gcp/comparison.html (last updated Mar. 10, 2009). All institutions
receiving HHS funding must provide the Department with assurances that every project
conducted at the institution, regardless of the source of funding, will abide by the human
subjects protection regulations. See 45 C.F.R. § 46.103(a) (2013).
65. Variations in IRB workload, institutional support and resources, and attitudes towards
the informed consent process can lead to significant differences in the implementation of the
federal regulations among boards, thereby potentially compromising this core mission. See
JESSICA BERG ET AL., INFORMED CONSENT: LEGAL THEORY AND CLINICAL PRACTICE 259 (2d ed.
2001); Jerry Goldman & Martin D. Katz, Inconsistency and Institutional Review Boards, 248
JAMA 197, 197, 198-99 (1982) (analyzing how 22 different IRBs reviewed identical research
protocols, and reporting “substantial inconsistency” among boards in the application of both
regulatory requirements for informed consent and ethical principles); Rita McWilliams et al.,
Problematic Variation in Local Institutional Review of a Multicenter Genetic Epidemiology
Study, 290 JAMA 360, 360, 364-65 (2003) (evaluating the review by 31 different IRBs of a
multicenter cystic fibrosis genetic study, and concluding that the “highly variable” approaches
of different boards compromised human subjects protection and created inefficiencies).
66. See 45 C.F.R. § 46.111(a)(1) (2013).
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scientific knowledge.67 Thus, the IRB must attempt to quantify and weigh
potential risks and benefits to subjects associated with participation in the
research.68 This inquiry is necessarily complex and fact-intensive, and
obviously more so in proposals to study the safety and efficacy of drugs in
pregnant women because of the prospect of dual risk to both mother and
fetus. In the case of therapeutic research, where the subjects suffer from the
condition under investigation, there are both potential risks and direct
benefits to participation. In non-therapeutic research, however, there is no
prospect of direct benefit to the participants. In such cases, the IRB evaluates
whether the possible benefit to society in the form of improved scientific
understanding justifies the risks to individual research participants.69 As
explained within, virtually all research involving pregnant women must offer
67. See id. § 46.111(a)(2). IRBs do not, as a general matter, consider the ultimate cost of
an experimental therapy, though perhaps they should. After all, if the experimental product will
be very expensive compared with other available, efficacious therapies and thus will not
constitute an important addition to the treatment arsenal for a particular condition, perhaps
the benefits of the research may not justify its risks. Because the cost of some new therapies
appears justified in patients who do not respond well to cheaper alternatives, however, and
because IRBs have no crystal ball to determine which new therapies will fill such a niche, cost
generally remains irrelevant to the IRB’s assessment of the value of the potential scientific
knowledge being sought. Compare Jean-Michel Gaspoz et al., Cost Effectiveness of Aspirin,
Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease, 346 NEW ENG. J.
MED. 1800, 1803-04 (2002) (concluding that the use of aspirin alone was the most costeffective treatment for cardiac patients despite the fact that adding the more expensive drug
clopidogrel increased therapeutic benefit), with Alastair J.J. Wood, When Increased
Therapeutic Benefit Comes at Increased Cost, 346 NEW ENG. J. MED. 1819, 1820 (2002)
(criticizing the study authors’ recommendations, and arguing that the search for improved
drug therapies should not be abandoned based on concerns about what they characterized as
“unattractive” cost).
68. See 45 C.F.R. § 46.111(a)(2) (2013) (“In evaluating risks and benefits, the IRB should
consider only those risks and benefits that may result from the research (as distinguished from
risks and benefits of therapies subjects would receive even if not participating in the
research)”). Not surprisingly, it is sometimes difficult for the subjects themselves to separate
research-related treatments from standard therapies, especially if they are receiving both
simultaneously and, therefore, difficult for prospective research subjects to weigh risk and
benefit in deciding whether to participate. See supra notes 65-67, infra note 69 and
accompanying text. Although the regulations only require IRBs to categorize risk for research
involving children, see 45 C.F.R. § 46.404, it is common practice for IRBs to categorize risk in
all research protocols. In the context of research on adults, the federal regulations only define
“minimal risk.” See id. § 46.102(i). Thus, IRBs must use their own judgment in determining
what research activities constitute “greater than minimal risk.” Id. § 46.404.
69. For example, Phase I clinical trials to assess the safety and appropriate dosing levels
of an investigational new drug provide no direct benefit to the study subjects but represent a
necessary step in the development of potentially useful drug therapies that ultimately may
benefit large numbers of patients. An IRB may conclude that such research, if appropriately
designed, meets the ethical standards implicit in the regulations.
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the prospect of direct benefit to mother or fetus in order to satisfy ethical and
regulatory requirements.70
IRBs also must assess the scientific merit of each research proposal, a
task that includes risk-benefit analysis but also considers the place of a
particular research plan in the broader field of scientific inquiry. Research
that lacks scientific merit is per se unethical and must not receive IRB
approval. The assessment of scientific merit may prove difficult, however,
even for a board of scientists and physicians. For example, if a protocol is
designed to assess the safety and efficacy of a drug that will be the tenth in
its therapeutic class and the study involves significant risk of side effects, the
IRB may opt against approval. Similarly, IRBs may reject placebo-controlled
studies that deny participants access to available standard therapy.71 In
contrast, the IRB may more willingly tolerate a significant degree of risk to
participants in a drug study involving a new molecular entity or other novel
therapy intended to treat a serious or life-threatening condition for which
available treatments are inadequate, even when the investigator provides
only limited pre-clinical and clinical data about safety and effectiveness.72 In
the case of research evaluating the safety and efficacy of prescription drugs
in pregnant women, the IRB should consider as part of its risk-benefit
calculus the frequency with which the drug is prescribed to this population,
the severity of the condition that the drug is meant to treat and, of course,
any known information about risk to the fetus.73 All of these factors, taken
together, provide some window into the scientific merit of the research plan,
but without much data on which to base these evaluations, the IRB may be
working in the dark.
The informed consent process is designed to reduce the knowledge gap
between physician and patient by mandating the communication of
70. See infra notes 84-89 and accompanying text.
71. See, e.g., Ezekiel J. Emanuel & Franklin G. Miller, The Ethics of Placebo-Controlled
Trials – A Middle Ground, 345 NEW ENG. J. MED. 915, 915 (2001) (arguing that “placebo
controlled trials are permissible when proven therapies exist, but only if certain ethical and
methodologic criteria are met”); Benjamin Freedman et al., Placebo Orthodoxy in Clinical
Research II: Ethical, Legal, and Regulatory Myths, 24 J.L. MED. & ETHICS 252 (1996)
(challenging a number of common beliefs concerning the value of placebo controls); Sharona
Hoffman, The Use of Placebos in Clinical Trials: Responsible Research or Unethical Practice?,
33 CONN. L. REV. 449, 475-95 (2001) (describing and discussing the competing arguments).
72. See Karen Antman et al., Designing and Funding Clinical Trials of Novel Therapies,
344 NEW ENG. J. MED. 762, 762 (2001) (observing that “[t]here are no clear criteria for
determining when a procedure is optimally developed and when it is ready for randomized
testing”).
73. See infra notes 84-89, 100-03 and accompanying text (discussing the regulations
that specifically apply to research involving pregnant women and the challenges to IRBs and
investigators in their implementation).
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sufficient information to allow the patient to make meaningful decisions
about healthcare.74 It serves much the same purpose for potential clinical
trial subjects and the researchers. Informed consent represents a necessary,
though not sufficient, requirement for ethically appropriate research.75 The
regulations require that investigators obtain and document informed consent
from each research subject,76 but, of course, since the fetus cannot provide
separate consent, the pregnant woman must make the decision whether to
participate, taking into account the interests of the fetus. The consent form
must use language that the subject can comprehend.77 Both sets of
regulations demand essentially identical elements in the disclosure of
research procedures and risks to potential participants, including a
description of the procedures to be followed, identification of any
procedures which are experimental, a description of any reasonably
foreseeable risks or discomforts to the subject, a description of any
prospective benefits to the subject or to others, a discussion of alternative
procedures or courses of treatment, if any, that might be advantageous to
the subject, and a statement that participation is voluntary and that the

74. See Robert Gatter, Informed Consent Law and the Forgotten Duty of Physician Inquiry,
31 LOY. U. CHI. L.J. 557, 558 (2000); Joan H. Krause, Reconceptualizing Informed Consent in
an Era of Health Care Cost Containment, 85 IOWA L. REV. 261, 267-78 (1999).
75. See Ezekiel J. Emanuel et al., What Makes Clinical Research Ethical?, 283 JAMA
2701, 2702-07 (2000) (discussing seven requirements, including informed consent, essential
to the conduct of truly ethical research). See also Richard W. Garnett, Why Informed Consent?
Human Experimentation and the Ethics of Autonomy, 36 CATH. U.L. REV. 455, 476-77 (1996)
(explaining that informed consent in research pays “comparatively little attention” to whether
the experiment itself is ethical).
76. See 45 C.F.R. § 46.111(a)(4)-(5) (2009).
77. See id. § 46.111. Despite the fact that many IRBs have interpreted the “language
understandable to the subject” clause in this regulation to require informed consent forms to
be written at an 8th grade reading level, IRBs have difficulty interpreting and enforcing this
standard and comprehension problems remain. See Stanley Blenkinsop, Whatever Happened
to Plain English? The Gobbledygook Smokescreen that Baffles Research Subjects, in
VOLUNTEERS IN RESEARCH AND TESTING 76, 89-93 (Bryony Close et al. eds., 1997) (observing
that “[t]here must be some suspicions that those unable to organise a clear, effective written
explanation are equally unable to organise a clear, effective research programme,” and
providing some egregious examples of consent form “gobbledygook” with translations); Dale
E. Hammerschmidt & Moira A. Keane, Institutional Review Board (IRB) Review Lacks Impact on
the Readability of Consent Forms for Research, 304 AM. J. MED. SCI. 348, 349-50 (1992)
(concluding that the IRB review process only improved consent form readability by an average
of one-tenth of a grade level); Michael K. Paasche-Orlow et al., Readability Standards for
Informed-Consent Forms as Compared with Actual Readability, 348 NEW ENG. J. MED. 721,
723-24 (2003) (providing examples of informed consent text at a variety of reading levels,
and concluding that most medical schools did not comply with their own internal readability
requirements).
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subject may discontinue participation at any time without penalty.78 Once
the IRB approves the protocol and the consent form, the process of
obtaining consent is left to the principal investigator or, more often, to his or
her staff.79 Unfortunately, the actual process of obtaining consent in
research often emphasizes form over substance and thus falls short of
promoting the ethical ideal of patient autonomy in making medical
decisions.80
IRBs suffer from significant limitations that impede their mission.81
Conscientious compliance with the minimal standards in the federal rules
satisfies only a portion of the legal and ethical obligations in clinical
research. Because the regulations only provide basic parameters for
acceptable research, IRBs and investigators must exercise judgment in the
interpretation and implementation of the rules. Understandably, caution
prevails, both because of concerns about participant safety and potential
liability should injury occur.

78. 45 C.F.R. § 46.116(a) (2009). In certain cases, the regulations require additional
consent information, including statements about the risk to the fetus where the research
involves pregnant women, circumstances under which the subject’s participation may be
terminated by the investigator, additional costs to the subject, and the number of subjects
involved in the study. See § 46.116(b).
79. The IRB has the option of appointing a “consent monitor” to oversee this process. See
§ 46.109(e). IRBs rarely have the resources to exercise this authority.
80. See BERG ET AL., supra note 65, at 200. According to Franz Ingelfinger, “[t]he patient,
asked to sign countless releases or consents, may respond with a . . . pro forma signature. The
physician, immersed in a profusion of unimportant detail, will lose sight of, and respect for the
important issues . . . . For medical ethics, in short, trivialization is self-defeating.” Id. For a
detailed discussion of these points, including a critique of the practice of obtaining consent in
the research context, see Richard Delgado & Helen Leskovac, Informed Consent in Human
Experimentation: Bridging the Gap Between Ethical Thought and Current Practice, 34 UCLA L.
REV. 67, 75-80 (1986).
81. See Noah, supra note 57, at 196-206 (describing the changing climate of medical
research – particularly pressures arising from increased research volume, the lack of effective
training mechanisms, lack of expertise on IRBs in highly specialized fields of medicine, and
complex relationships between academic researchers and private funding sources – increases
the likelihood that these boards will fail in their mission to protect human subjects. In addition
to failures to comply with explicit human subjects protection regulations, IRBs may
underestimate risks, miss ethical or scientific deficiencies in the design of research protocols,
or make other similar errors of judgment, thereby subjecting unwitting research participants to
inappropriate and avoidable jeopardy. IRBs increasingly may face tort liability for “bioethical
malpractice” — a failure to exercise reasonable judgment within the confines of the regulatory
scheme governing human subjects research).
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Clinical Research Regulations Governing Research with Pregnant
Women

In recognition of past episodes of research abuse, the federal
government also has promulgated regulatory protections providing
additional safeguards to protect “vulnerable populations” in clinical
research, including children, prisoners, pregnant women, the physically or
mentally disabled, and educationally and economically disadvantaged
individuals.82 The regulations pertaining to research involving pregnant
women, human fetuses, and neonates set out requirements that IRBs and
clinical investigators must meet in addition to the basic clinical research
requirements in order to conduct research in this sub-population.83 The
regulations operate with a presumption of exclusion and only permit
inclusion under very limited circumstances.
The current regulations require compliance with the following conditions
in order for research involving pregnant women to be approvable: 1) if
scientifically appropriate, preclinical studies, including animal studies and
clinical studies on nonpregnant women, provide data to assist in risk
assessment; 2) any risk to the fetus arises from interventions that also offer
the prospect of direct benefit to the women or the fetus; or if there is no
prospect of direct benefit, the risk to the fetus is no more than minimal and
the research will likely assist in the development of important medical
knowledge; 3) risks in the research are minimized as much as possible; 4)
consent of the pregnant woman is required for research that offers the
prospect of direct benefit to the pregnant woman and her fetus, the
pregnant woman alone, or is minimal risk research with the prospect of
obtaining important medical knowledge; 5) consent of the pregnant woman
and the father is required for research that offers the prospect of direct
benefit solely to the fetus (unless the father is unavailable, incapacitated, or
the pregnancy has resulted from rape or incest); and 6) no monetary or

82. See 45 C.F.R. § 46.111(b) (2009). The federal research regulations do not, of
course, reach research conducted in foreign countries, though other international standards
on medical research such as the Nuremberg Code and the Declaration of Helsinki serve to
protect foreign research subjects. Commentators strongly criticized overseas trials on
maternal-fetal AIDS transmission using a placebo control because these trials violate basic
international principles of human subjects protections. For more on the international
dimensions of human subjects protections and vulnerable populations, see Jonathan Todres,
Can Research Subjects of Clinical Trials in Developing Countries Sue Physician-Investigators for
Human Rights Violations?, 16 N.Y.U L. SCH. J. HUM. RTS. 737 (2000); Harold Varmer & David
Satcher, Ethical Complexities of Conducting Research in Developing Countries, 337 NEW ENG.
J. MED. 1003 (1997).
83. See 45 C.F.R. § 46.203 (2009).
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other inducements can be offered to the pregnant woman to terminate her
pregnancy.84
Several aspects of these regulations pose implementation or interpretive
issues for IRBs. For example, the requirement that IRBs look for preclinical
studies, including animal studies, for information to assist in risk assessment
may create a de facto pattern of non-approval of research protocols that
lack preclinical safety data.85 Similarly, the question of whether proposed
research creates a risk to the fetus that is “no more than minimal” leaves
IRBs struggling to define the meaning of “minimal risk.”86 More generally,
quantifying risk and benefit in the context of proposed research with
pregnant women is a very subjective process which is likely to vary
considerably from one IRB to another.87
By limiting research in pregnant women to those interventions (including
prescription drugs) that either offer the prospect of direct benefit to the
mother or fetus, or are otherwise posing no greater than minimal risk, the
regulations take a very conservative stance on safety and have the effect of
making some important research with pregnant women unapprovable. The
regulations do include an exception for research that is not otherwise
approvable, allowing HHS to conduct research that “presents a reasonable
opportunity to further the understanding, prevention, or alleviation of a
serious problem affecting the health or welfare of pregnant women, [and]
fetuses,”88 but the procedural requirements are onerous. The regulations
require that the Secretary of HHS consult with an expert panel, publish a
notice and opportunity for comment about the proposed research in the
Federal Register, and must, based on comments and the deliberations of the
expert panel, conclude either that the research does in fact satisfy the
requirements above or that the research will be conducted according to
sound ethical principles and appropriate consent will be obtained.89 It is not
difficult to imagine that various constituencies concerned with fetal life might
register objections to clinical research involving pregnant women in these
circumstances.
The presumption against inclusion of pregnant women in clinical
research remains for now, but, at least as to research involving drugs that
84. See 45 C.F.R. § 46.204(a)-(e), (h) (2009).
85. See ORWH REPORT, supra note 5, at 39 (suggesting that “IRBs [may] wonder how
much preclinical research is enough to ensure that there will be no harm to the fetus” and
predicting that IRBs will be “conservative[]” in this assessment).
86. Cf. Foulkes et al., supra note 2, at 1431 (calling for “more regulatory clarity” with
respect to what constitutes minimal risk to the fetus).
87. See ORWH REPORT, supra note 5, at 39.
88. See 45 C.F.R. § 46.207(a) (2013).
89. See 45 C.F.R. § 46.207(b)(1)-(2) (2013).
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are regularly prescribed to pregnant women, the regulatory and research
communities ought to consider the possibility of inclusion as a matter of
routine, at least when the risk-benefit ratio appears favorable. The current
regulations operate in exactly the opposite fashion, discouraging inclusion
in a misguided attempt to avoid challenging ethical issues, possible injuries
to research participants and fetuses, and potential liability. Of course these
are genuine challenges, and it is impossible to eliminate them completely.
At the same time, leaving pregnant women with the choice of foregoing
medically necessary therapy or taking an untested drug and hoping for the
best is clinically and ethically unacceptable.
III. SPECIAL CHALLENGES FOR RESEARCH WITH PREGNANT WOMEN
For both investigational new drugs and other types of biomedical
research, the desire to streamline clinical trials in order to produce
statistically significant results has led investigators to prefer homogenous
patient populations for many types of studies. Until relatively recently,
investigators almost uniformly tested new chemical entities only on white
male subjects.90 Although testing drugs in a homogenous white male
population simplifies data collection and may generate clearer statistical
differences between an investigational drug and an active or placebo
control, this type of study design provides no information about the safety or
effectiveness of the therapy in excluded sub-populations.91 Researchers also
feared that women of childbearing age could become pregnant during
research, and so routinely excluded women on this basis in order to avoid
potential liability.92 In the past, commentators have devoted a good deal of
attention to the inclusion of women in clinical trials.93 Despite this attention
90. See Noah, Underrepresented Minorities, supra note 3, at 221 (discussing reasons for
the exclusion of racial minorities including a history of distrust on the part of African American
and other racial minorities of the medical research establishment and suggesting benefits of
inclusion of these populations along with appropriate safeguards and considerations).
91. See Craig K. Svensson, Representation of American Blacks in Clinical Trials of New
Drugs, 261 JAMA 263, 263-65 (1989).
92. See ORWH REPORT, supra note 5, at 7 (adding that this fear of liability was common
despite a low number of research injuries and few lawsuits regarding such injuries).
93. See, e.g., Vanessa Merton, The Exclusion of Pregnant, Pregnable, and OncePregnable People (a.k.a. Women) from Biomedical Research, 19 AM. J.L. & MED. 369, 372
(1994); Joan W. Scott, How Did the Male become the Normative Standard for Clinical Drug
Trials?, 48 FOOD & DRUG L.J. 187, 187-88 (1993) (describing two contradictory assumptions
– that women are identical to men so that female participation in drug trials is unnecessary,
and that women are so unlike men that female participation in drug trials would destroy the
purity of the experiment – that have contributed to this phenomenon); L. Elizabeth Bowles, The
Disenfranchisement of Fertile Women in Clinical Trials: The Legal Ramifications of and
Solutions for Rectifying the Knowledge Gap, 45 VAND. L. REV. 877, 890 (1992).
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to the issue in the literature, women still are underrepresented in many types
of clinical trials.94 The effect of gender imbalance in clinical research over
time is “pernicious: medicine as it is currently applied to women is less
evidence-based than that being applied to men.”95
In 2001, the National Institutes of Health (NIH) published guidelines on
the inclusion of women in research that state that “[i]t is the policy of NIH
that women and members of minority groups and their subpopulations must
be included in all NIH-funded clinical research, unless a clear and
compelling rationale and justification establishes to the satisfaction of the
relevant Institute/Center Director that inclusion is inappropriate with respect
to the health of the subjects or the purpose of the research.”96
Unfortunately, the NIH policy is silent on the matter of including pregnant
women in research.
A.

Ethical Arguments for Inclusion of Pregnant Women in Research

It is well-established that both the quantity and quality of safety data for
prescription drugs in pregnancy is limited. The single most compelling
argument for the inclusion of pregnant women in clinical research is that
women, including those who are pregnant, deserve the same evidencebased medicine (in the form of safety data about prescription medications)
that is available to others who take a prescription drug. As one
commentator explains, “[t]o exclude any group or population from
participating in medical research results in a lack of knowledge about the
risks and potential benefits of products that will be available for their use
once on the market.”97 The usual procedure has been to remove a woman
from a clinical trial if she becomes pregnant and then follow up to collect
any information about adverse events, but the problem with this approach is
that, for many drugs, harm may occur at different gestational periods, not
only in the early stages of pregnancy.98 Studying drug safety throughout

94. See Françoise Baylis, Pregnant Women Deserve Better, 465 NATURE 689, 689
(2010); Alison M. Kim et al., Sex Bias in Trials and Treatment Must End, 465 NATURE 688,
688 (2010).
95. Editorial, Putting Gender on the Agenda, 465 NATURE 665, 665 (2010) (adding that
enrolling pregnant women in clinical research is fraught with ethical problems but that
“ignoring the problem is not an answer either”).
96. See Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in
Clinical Research – Amended, October 2001, NAT’L INSTS. OF HEALTH, http://grants.nih.gov/
grants/funding/women_min/guidelines_amended_10_2001.htm (last updated Oct. 1, 2001).
97. See Ruth Macklin, The Art of Medicine: Enrolling Pregnant Women in Biomedical
Research, 375 LANCET 632, 632 (2010).
98. See id. at 633.
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pregnancy will provide more data about risks associated with particular
drugs.
In addition to the risk of harm to the mother or fetus from prescribing
medication with an undetermined safety profile, there are other ethical
arguments for inclusion of pregnant women. In the current climate in which
physicians understand that there is a risk to the fetus with prescribing many
unstudied medications, physicians may be hesitant to provide a pregnant
woman with medically necessary treatment (for fear of injuring the fetus),
therefore depriving her of potentially beneficial care. The failure to treat
pregnant women for chronic or episodic illness can create riskier situations
for the woman and/or her fetus than the use of an appropriate
medication.99
Although various governmental and private organizations have strongly
encouraged the inclusion of pregnant women in research, there are
problems with implementation of this still mainly aspirational goal. For
example, the Council for International Organizations of Medical Sciences
(CIOMS) published its Guidelines for Biomedical Research Involving Human
Subjects, which states that pregnant women should be presumed eligible for
biomedical research.100 The commentary on this particular statement
demonstrates some of the complexities that arise with implementation. If
there is potential risk to the fetus and the research goals are directed
towards the health of the fetus, the commentary suggests that the
investigators should seek the father’s opinion, when feasible, as well as the
mother’s consent.101 In addition to adding to the burden of conducting the
research in general, it is reasonable to expect that, at least some of the time,
seeking paternal assent will reveal a disagreement between the parents
about the appropriateness of participation. What role then should the
researcher play? And should the mother’s consent trump the father’s

99. See Lyerly et al., supra note 8, at 11-12 (discussing the risks of non-treatment or
undertreatment of depression and asthma during pregnancy).
100. See, e.g., COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES (CIOMS),
INTERNATIONAL ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS 74
(2002), available at http://www.cioms.ch/publications/layout_guide2002.pdf. Guideline 17
states, “Pregnant women should be presumed to be eligible for participation in biomedical
research. Investigators and ethical review committees should ensure that prospective subjects
who are pregnant are adequately informed about the risks and benefits to themselves, their
pregnancies, the fetus and their subsequent offspring, and to their fertility. Research in this
population should be performed only if it is relevant to the particular health needs of a
pregnant woman or her fetus, or to the health needs of pregnant women in general, and,
when appropriate, if it is supported by reliable evidence from animal experiments, particularly
as to risks of teratogenicity and mutagenicity.”
101. See id.
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disagreement? This requirement of paternal consent “when possible” is also
inconsistent with the HHS regulations which mandate paternal (as well as
maternal) consent for research that poses more than minimal risk but offers
the prospect of benefit only to the fetus.102
The CIOMS commentary also recognizes that, in some cultures or
communities, the fetus’s health is considered more important than that of
the mother and so suggests that “women may feel constrained to
participate, or not to participate, in research” and that “[s]pecial safeguards
should be established to prevent undue inducement to pregnant women to
participate in research in which interventions hold out the prospect of direct
benefit to the fetus.”103 Again, it is important to recognize this point, but how
should researchers or IRBs prevent inducement to pregnant women? These
sorts of concerns, taken together with the natural ambivalence that many
pregnant women will feel when considering research participation, are not
easily answerable, but carefully considered and articulated standards for
study design and inclusion can at least help to normalize participation and
improve the consistency of IRB review and supervision of research protocols
that include pregnant women.
B.

Recommendations for Ethically Appropriate Research Models

The Randomized Controlled Trial (RCT) is still generally thought to be
the gold standard of clinical investigation.104 In general, new drugs and
therapies undergo three phases of clinical testing after the completion of in
vitro and animal studies. In the case of novel therapies, investigators may
require several Phase II studies to evaluate technical feasibility questions, in
addition to efficacy, before proceeding to Phase III trials that actually test the
efficacy of investigational therapies in larger numbers of subjects who suffer

102. See supra note 84 and accompanying text.
103. See COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES, supra note
100, at 74.
104. See Ulrich Abel & Armin Koch, The Role of Randomization in Clinical Studies: Myths
and Beliefs, 52 J. CLINICAL EPIDEMIOLOGY 487, 487 (1999); Stuart J. Pocock & Diana R.
Elbourne, Randomized Trials or Observational Tribulations, 342 NEW ENG. J. MED. 1907,
1907 (2000) (advocating continued emphasis on RCTs, in part because in observational
studies the treatment is selected for the particular patient and this selection bias may create
cumulative outcome differences that are not a result of the treatment itself). But see Kjell
Benson & Arthur J. Hartz, A Comparison of Observational Studies and Randomized, Controlled
Trials, 342 NEW ENG. J. MED. 1878, 1883 (2000) (concluding that observational studies and
RCTs were equally useful in accurately assessing the treatment effects of a wide variety of
therapies); John Concato et al., Randomized Controlled Trials, Observational Studies, and the
Hierarchy of Research Designs, 342 NEW ENG. J. MED. 1887, 1890 (2000).
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from the targeted medical condition.105 In contrast to RCTs, collecting data
retrospectively from case reports or adverse event reports provides some
information, but the low numbers of such reports usually means that the
data are not statistically significant enough to conclude that a particular
drug presents a particular risk in excess of the baseline risk.106 Data from
surveys can also lead to faulty conclusions when the response rate is poor,
and uncontrolled studies that do not exclude confounding variables can also
generate data of questionable validity.107
Commentators have suggested that randomized clinical trials with
pregnant women may be ethically acceptable under limited circumstances,
specifically when they include careful assessment of scientific merit that
concludes that a clinical trial of a particular drug is ethically justified under
the circumstances. For example, such trials may be appropriate for drugs to
treat conditions that affect pregnant women and for which there are no
other acceptable treatments and for drugs that are designed specifically to
treat pregnancy-related conditions.108 Such studies might also be ethically
appropriate in cases where pregnant women are already regularly taking a
marketed drug and it has an established safety profile based on post-market
reports.109 Additional study in an RTC in such circumstances could confirm
initial conclusions about safety, efficacy, and dosing or may also detect
previously unknown risks. When RCTs do include pregnant women, it is
important that the reviewing IRB consider risks and benefits to both mother
and fetus holistically,110 not an easy task.
In the medical and ethics literature, commentators have suggested a
number of strategies to minimize the risk of such research when it is
conducted, including waiting to begin the research until there is sufficient
pre-clinical data on which to assess toxicity, and monitoring the pregnancy
105. See LARS NOAH & BARBARA A. NOAH, LAW, MEDICINE, AND MEDICAL TECHNOLOGY: CASES
MATERIALS 137-52 (2002) (discussing the various phases of drug development). In Phase I,
a small number of healthy volunteers participate in a study to measure toxicity and to
determine appropriate dosing. In Phase II, a somewhat larger number of individuals with the
targeted disease or condition test the drug for efficacy and risks associated with its use. Finally,
in Phase III, a large population of individuals with the targeted disease, along with a control
group of some sort, test the product’s safety and efficacy. See id. at 145-46.
106. See Christina D. Chambers et al., Human Pregnancy Safety for Agents Used to Treat
Rheumatoid Arthritis: Adequacy of Available Information and Strategies for Developing PostMarketing Data, 8 ARTHRITIS RESEARCH & THERAPY 225, 231 (2006).
107. See id. (adding that “information on outcomes is often incomplete without
comprehensive data on the range of outcomes, including malformations, fetal growth and
preterm delivery”).
108. See Goldkind et al., supra note 10, at 2243.
109. See id. at 2242-43.
110. See Foulkes et al., supra note 2, at 1431.
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via ultrasound and fetal heart monitoring in order to determine whether or
when a particular subject should withdraw from the research.111 The
supervising IRB can also require that the trial be monitored by a Data Safety
Monitoring Board (DSMB) in order to collect information about adverse
events as the study is ongoing and respond quickly to evidence of toxicity,
teratogenicity, or other problems.112
To state the obvious, the informed consent process with pregnant
women in research must be thorough and meaningful. The consent process
should include discussion of the known and potential risks of harm to the
pregnant woman and her fetus and should afford the woman an opportunity
to ask questions. This consent is always required in research, but, given the
dual risk to the woman and her fetus, it deserves extra care in this context.113
At the same time, while informed consent is very important, viewing
pregnant women as a “vulnerable” population seems, in some respects,
inapt. While it may be true that the captive fetus is vulnerable to the results
of the woman’s decision whether or not to participate in clinical research, it
is surely not correct to suggest that pregnant women are somehow less able
to provide valid informed consent to participation. Given the fact that
regulations in the United States already require consent from the father
under some circumstances, the combination of excessive paternalism and
zero risk tolerance114 will continue to limit the opportunities for pregnant
women to participate in research.
The federal regulations provide little guidance to investigators and
research participants about how to evaluate risk in these circumstances. For
this reason, a number of commentators have identified these gaps and

111. See Goldkind et al., supra note 10, at 2243 (adding that sufficient evidence of adverse
effects might also require cessation of the entire clinical trial).
112. Some research protocols include a provision requiring ongoing supervision of
approved research (between continuing reviews by the IRB) by an oversight committee such as a
DSMB. IRBs have the authority to require DSMB oversight when they believe it to be
appropriate. The NIH also requires that all NIH-funded trials have an appropriate oversight
system, including DMBs for certain types of clinical trials. See Jay Herson, Data Monitoring
Boards in the Pharmaceutical Industry, 12 STAT. MED. 555, 555-61 (1993) (describing the
duties of these boards in different contexts such as NIH clinical trials and industry-sponsored
trials); Michael A. Morse et al., Monitoring and Ensuring Safety During Clinical Research, 285
JAMA 1201, 1202 (2001) (describing the role of these boards in analyzing data from trials in
progress).
113. See Macklin, supra note 97, at 633 (adding that IRBs will no doubt police consent
carefully in this context but that “ultimately the responsibility falls to the investigators to ensure
that all relevant information is presented and understood”).
114. See Lyerly et al., supra note 8, at 14 (explaining that “the need for thoughtful criteria
has been eclipsed by a social tendency to regard the very idea of trading off risks between the
woman and her fetus . . . however theoretical or small . . . as anathema”).
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ambiguities in the federal research regulations and have offered specific
analytical frameworks, consistent with the regulations, to guide IRBs and
clinical investigators in filling those gaps. For example, one group of
commentators has recommended a framework to evaluate risk and benefit
to the mother and fetus, depending on the nature and goals of the research
protocol.115 If the research is intended primarily to benefit the mother,116 this
framework proposes that mothers of previable fetuses retain the right to
decide whether to confer dependent moral status on the fetus and thereby
make decisions about research participation with beneficence towards the
fetus in mind.117 For research that potentially affects viable fetuses, the
framework suggests that “[t]he viable fetus is a patient in virtue of both its
ability to survive ex utero and its access to medical technology that makes
this possible . . . .”118 These commentators therefore suggest that, in the
case of viable fetuses and previable fetuses on whom the mother confers
moral status, research for the benefit of the pregnant woman requires
balancing maternal and fetal interests. The consent process in this context
should ask the pregnant woman to balance her obligation to protect the
fetus against her own health interests in participating in the research.119 This
proposed framework, while consistent with the federal regulatory
requirements, is not anywhere explicit in these regulations. Other
commentators have commended these efforts but also offered critiques. In
particular, these commentators have challenged the proposed framework as
accepting without protest the presumption of exclusion and potentially
posing yet another potential obstacle to the inclusion of pregnant women in
research.120

115. See McCullough et al., supra note 7, at 902-03.
116. By contrast, for research intended primarily to benefit the fetus, such as surgical
treatment in utero of spinabifida, the study should be designed in such a way that pregnant
subjects are exposed only to reasonable risks to their own health. See id. at 903.
117. See id. at 902 (explaining that “[t]he previable fetus is a patient solely as a function of
the pregnant woman’s autonomy”).
118. See id.
119. See id. at 903.
120. See Chris Kaposy & Francoise Baylis, The Common Rule, Pregnant Women, and
Research: No Need to”Rescue” that which should be Revised, 11 AM. J. BIOETHICS 60, 60
(2011) (“At worst, the proposed framework could be another deterrent to such research by
introducing additional barriers, and potentially ghettoizing research involving pregnant
women.”); Anne Drapkin Lyerly et al., Reframing the Framework: Toward Fair Inclusion of
Pregnant Women as Participants in Research, 11 AM. J. BIOETHICS 50, 50 (2011) (noting,
among other criticisms, that the framework “appears to adopt a default position that current
practice is necessarily safer or otherwise in the best interests of pregnant women or their
fetuses than participation in research, despite the absence of evidence for the medical
management of many medical conditions and risks experienced by pregnant women”).
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The United States is not alone in its struggle to articulate the appropriate
circumstances for the inclusion of pregnant women in RCTs and other sorts
of research models that expose the woman or fetus to risk. The clinical
research communities in other countries also struggle to describe those
circumstances in which inclusion of pregnant women in clinical research are
appropriate. Health Canada, for example, published a guidance document
in 2012 which indicates conditions in which the inclusion of pregnant
women in clinical research may be ethically acceptable.121 These conditions
include the following:
(i) The specific use of the therapeutic product is for pregnant or
breastfeeding women (e.g. for obstetrical or pregnancy related problems).
(ii) The studies are of agents which can be expected to address an unmet
maternal /foetal risk or disease (e.g. pregnant women with HIV; other life
threatening conditions) and where there are no alternatives available on the
market.
(iii) The studies are of agents which can be expected to improve
maternal/foetal outcomes as compared to existing therapy.
(iv) Animal studies have been conducted, including studies on pregnant
animals, and there is data on non pregnant women on which to base an
estimate of risk to the woman and/or foetus.
(v) For a new drug or new indication there is anticipated or actual use of
the drug in pregnant women and women of childbearing potential.
(vi) The woman and/or foetus will benefit directly from participation and
where any potential benefit to the foetus should be weighed against possible
risks to the mother.
(vii) The risk to the foetus is not greater than that from established
procedures routinely used in an uncomplicated pregnancy, or in a
pregnancy with complications comparable to those being studied, and the
purpose of the research is the development of biomedical knowledge which
cannot be obtained by any other means.
(viii) The woman is fully informed of the risks to her, the foetus and the
newborn . . . .122

In all of these circumstances, the emphasis is on balancing unknown risk
against speculative prospective benefit. The prospect of direct benefit, as in
cases where the study drug is anticipated to be used in pregnant women,

121. See HEALTH CANADA, HEALTH CANADA GUIDANCE DOCUMENT, CONSIDERATIONS FOR
INCLUSION OF WOMEN IN CLINICAL TRIALS AND ANALYSIS OF DATA BY SEX (2012), available at
http://www.elsevierbi.com/~/media/Supporting%20Documents/The%20Gray%20Sheet/38/4
/Canada_draft_guidance.pdf.
122. See id. at 14.
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certainly would make participation more appealing for pregnant women
with the targeted medical condition. Nevertheless, there is no way to “fully
inform” the pregnant woman of the risks to her and the fetus; many of the
risks remain a known unknown.
Other research models offer the potential for data collection without the
ethical and regulatory complexity of RCTs. In addition to RCTs, another
approach to collect safety and efficacy data involves performing carefully
controlled pharmacokinetic studies (with sufficient numbers of pregnant
women for adequate statistical power) in groups of pregnant women who
are already taking the studied drug for therapeutic purposes.123 It would
also be useful to increase the prevalence of systematic observational studies
of the effects of drugs on pregnant women and fetuses in order to obtain
better quality data at a faster pace.124 Since 2007, the FDA has authority to
require Phase IV post-marketing trials as a condition of approval.125 In such
cases, the only added risk to the participating women and their fetuses
would come from the blood draws required to measure how the body
processes and excretes the drug. This approach represents a significant
improvement over collecting and collating spontaneous reports of adverse
events and offers the opportunity to detect adverse events more quickly and
to improve information about optimal dosing.
Another route for collecting data, Pregnancy Exposure Registry Studies,
involves enrolling pregnant women who are taking the drug in question for
therapeutic purposes in a registry which collects information about
outcomes.126 Although more information is better than less, critics of the
exposure registry approach to data collection point out that the outcomes
information is usually limited to major birth defects, thereby excluding

123. See Goldkind et al., supra note 10, at 2243.
124. Cf. C.D. Chambers et al., Drug Safety in Pregnant Women and their Babies:
Ignorance Not Bliss, 83 CLINICAL PHARMACOLOGY & THERAPEUTICS 181, 181 (2008) (observing
that, as of now, formal observational studies “are conducted in a piecemeal fashion for only a
small fraction of available medications through the uncoordinated efforts of various individual
investigators or state or federal agencies”).
125. See Food and Drug Administration Amendments Act of 2007 (FDAAA) § 901, 21
U.S.C. § 355(o) (2012) (authorizing the agency to require certain studies and clinical trials for
prescription drugs and biological products approved under Section 505 of the Federal Food,
Drug, and Cosmetic Act and requiring companies seeking marketing approval to provide to
the FDA information about required postmarketing studies or clinical trials such as the
timetable for completion and periodic status reports).
126. A list of pregnancy exposure registries may be found at List of Pregnancy Exposure
Registries, FOOD & DRUG ADMIN., http://www.fda.gov/scienceresearch/specialtopics/wo
menshealthresearch/ucm134848.htm (last updated Mar. 6, 2014). For a discussion of the
utility of pregnancy registries in the context of drugs for rheumatoid arthritis, see Chambers et
al., supra note 106.
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potential data about other adverse outcomes such as premature birth,
developmental issues, and other potentially detrimental effects.127
Nevertheless, a number of commentators have urged increased study of the
safety of various classes of drugs during pregnancy, recommending
organized retrospective data collection from pregnant women who must
take prescription drugs in order to understand the impact of medications on
the fetus.128 The FDA also published guidelines on the design of pregnancy
registries in order to address concerns about statistical power, more detail
about timing and duration of exposure to the studied drug, and more
detailed information about adverse outcomes, among other things.129
There are already some programs in place to collect and disseminate
information about pregnancy-related risks associated with certain drugs. The
FDA, in collaboration with various pregnancy registries, collects data from
pregnant women who take certain types of drugs in order to gather
statistically significant data about the association of a particular drug with a
birth defect. For example, the FDA recently released information about the
risk of oral clefts (cleft lip or palate) associated with the use of the antiseizure drug topiramate after the North American Antiepileptic Drug
Pregnancy Registry found that the data suggested an increased risk to the
fetuses of women taking this drug.130 Based on the new data, the FDA
recategorized the drug into pregnancy category D and advised women of
childbearing age to discuss alternative treatments with their healthcare
provider.131
The European Medicines Agency (EMEA) also has published a Guideline
that went into effect in 2006 and that recommends that manufacturers of
new drugs to the market collect data via pharmacovigilance programs.132

127. See Chambers et al., supra note 106, at 231-32.
128. See, e.g., Alwan et al., supra note 22, at 269; Chambers et al., supra note 124, at
182 (recommending a “national mandatory and systematic surveillance system for all newly
marketed drugs used by women of childbearing age”); Putting Gender on the Agenda, 465
NATURE 665, 665 (2010) (recommending systematic retrospective data gathering from all
women who have had to take prescription drugs during pregnancy).
129. See Guidance for Industry: Establishing Pregnancy Exposure Registries, FOOD & DRUG
ADMIN. (Aug. 2002), available at http://www.fda.gov/downloads/Drugs/GuidanceCompli
anceRegulatoryInformation/Guidances/ucm071639.pdf.
130. See Questions and Answers: Risk of Oral Clefts (Cleft Lip and/or Palate) in Infants
Born to Mothers Taking Topamax (Topiramate), FOOD & DRUG ADMIN. (last updated Mar. 7,
2011), http://www.fda.gov/Drugs/DrugSafety/ucm245470.htm.
131. See id.
132. See European Medicines Agency, Guideline on the Exposure to Medicinal Products
During Pregnancy: Need for Post-Authorisation Data, at 5-6, EMEA/CHMP/313666/2005
(Nov. 14, 2005), available at http://www.ema.europa.eu/docs/en_GB/document_library/
Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf.
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The Guideline also recommends similar data collection for already
marketed products in which safety during pregnancy is unknown.133 The
FDA and the EMEA share information from worldwide spontaneous
reporting of adverse effects, and take appropriate action when necessary.134
Collating spontaneous reports from multiple sources represents an
improvement over prior practices, although the inherent deficiencies of
spontaneous reporting remain.
The Organization of Teratology Information Specialists (OTIS) provides
a website with detailed factsheets about the known risks of a variety of
prescription and non-prescription drugs, herbal substances, and other
common substances used during pregnancy (such as alcohol and caffeine)
designed to educate mothers and prospective mothers about risks to the
fetus.135 In addition to providing risk information to expectant mothers, OTIS
conducts and collaborates in research designed to compile new information
about the risks of drugs during pregnancy. OTIS studies are designed to
compare three groups of women with a particular medical condition
requiring drug therapy. Group One includes women who have already
taken a medication or vaccine and who have a health condition that is
being studied. Group Two includes women who have the same health
condition but who have not taken medication to treat it. Group Three serves
as a control group and includes women who have neither taken the studied
medication nor have the medical condition that the medication is designed
to treat. By compiling comparative outcomes in pregnancy among all three
groups, these studies aim to contribute information about risks to fetuses of
various medications.136
The OTIS study model includes several important features that make it
superior to a traditional pregnancy registry, including the disease matched
group which consists of women who have the disease in question and have
133. See id. at 5-6.
134. For example, the EMEA publishes a monthly report by its Pharmacovigilance Working
Party that summarizes safety concerns associated with various types of drugs, including drugs
taken during pregnancy. See, e.g., Pharmacovigilance Working Party July 2011 Plenary
Meeting, July 18-20, 2011, Monthly Report, EMA/CHMP/PhVWP/569591/2011 (July 28,
2011) (describing the risk of side effects and withdrawal syndrome in newborns after exposure
to antipsychotic drugs during the third trimester of pregnancy and recommending that product
information in the EU contain additional information about this risk), available at
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109
581pdf.
135. See Fact Sheets, ORG. OF TERATOLOGY INFO. SPECIALISTS, http://www.mothertoba
by.org/otis-fact-sheets-s13037 (last visited Apr. 28, 2014).
136. See Influenza Vaccine & Antiviral Medications Study, ORG. OF TERATOLOGY INFO.
SPECIALISTS, http://www.mothertobaby.org/otis-research-study-participation-p150175 (last
visited Apr. 28, 2014).
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not taken the studied drug or drugs. Having a disease matched control
group allows for more accurate comparison of the rate of defects or other
adverse effects in the group taking the drug than would be possible with a
comparison of adverse effect rates in a broader background population.
Moreover, the OTIS model requires the participating women to make a
commitment to complete the study so that investigators typically get data
from 95% of the women in any given drug study group. And, because the
women remain in contact with the investigators throughout the course of the
pregnancy and beyond, investigators are better able to collect information
about potentially confounding variables such as non-prescription or herbal
drug use, alcohol or tobacco intake, and other possible toxin exposures.137
In addition to all of these benefits regarding the collection of more and
better data, participation in studies such as those conducted by OTIS
provides an “inclusion benefit” to the women in question. People in clinical
trials also seem to enjoy generally better health outcomes compared with
their peers who receive the same therapy outside of the study.138 This
“inclusion benefit,” though unrelated to the specific clinical purposes of the
study, represents a distinct and valuable bonus to those with limited access
to healthcare services.139
IV. CONCLUSION
The inclusion of pregnant women in clinical research deserves significant
additional attention and effort for reasons of scientific equity and justice. All
of the research models discussed above offer the prospect of increasing

137. See Chambers et al., supra note 124, at 232 (discussing the scientific superiority of
the OTIS study design compared with traditional pregnancy registries and noting that
participants get the added benefit of personal counseling about the risks of exposures to drugs
during their pregnancies).
138. Commentators have recognized that subjects enrolled in clinical trials, whether they
receive the experimental treatment or a placebo control, apparently achieve better outcomes
than patients with the same condition who receive treatment from physicians. See John D.
Lantos, The “Inclusion Benefit” in Clinical Trials, 134 J. PEDIATRICS 130, 130 (1999) (“A
number of explanations have been offered for the apparent benefit of RCT participation,
including selection bias, placebo effects, and adherence to well-defined protocols” for other
aspects of disease management.); Shankar Vedantam, Against Depression, A Sugar Pill is
Hard to Beat, WASH. POST, May 7, 2002, at A1. Of course, not all clinical research offers any
prospect of a therapeutic benefit.
139. In one survey of potential research participants, 53% of those questioned indicated
that they would be willing to participate in research in order to secure better medical care. See
Vickie L. Shavers et al., Factors that Influence African-Americans’ Willingness to Participate in
Medical Research Studies, 91 CANCER 233, 235 (2001). See also Gina Kolata & Kurt
Eichenwald, For the Uninsured, Drug Trials are Health Care, N.Y. TIMES, June 22, 1999, at
A1.
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access to safety and efficacy data in order to assist pregnant women and
their physicians in making decisions about the risks and benefits to woman
and fetus of prescription drugs at various stages of pregnancy. Although
there seems to be a growing sense that this research is ethically necessary
and appropriate, there does not (yet) appear to be much momentum to
initiate this research, particularly randomized, controlled trials. Ultimately,
the question is how we can move away from the presumed exclusion of
pregnant women to a routine practice of inclusion when scientifically and
ethically appropriate. This will require confronting valid fears of liability for
injuries to mother or fetus140 in a litigious society in which pro-life
constituencies also have significant influence on health policy.
Serious challenges in study design, IRB oversight, and research
participant safety make the thought of research in pregnant women
daunting, but it is important to find ways to monitor and acquire data about
the safety of commonly used drugs in pregnant patients. Pregnancy is a
common condition, even among women who suffer from serious and
chronic disease. Researchers must, therefore, design and conduct clinical
trials for both new and already-approved drugs and therapies that will
generate data for the safe use of these drugs. Phase IV trials involving
careful monitoring of efficacy and adverse events in pregnant patients who
receive approved drugs off-label will also contribute to the development of
better data on which to base prescribing decisions. There is a growing
consensus that RTCs are ethically appropriate under certain circumstances.
Moreover, the OTIS model of research represents a substantial improvement
over pregnancy registries and simple retrospective data collection.
It is no coincidence that pregnant women are the last “orphaned”
clinical trial population in the United States. The research community in the
United States is apparently reluctant to move forward with broader study of
the effects of prescription drugs in pregnant women for several reasons.
First, with the significant influence of the pro-life movement, it is likely that
the government (in its regulatory and research funding roles) and clinical
researchers are reluctant to risk the ire of political and religious conservative
organizations. At the urging of pro-life groups, a number of state
legislatures have considered “personhood” statutes that assign all of the
rights and privileges of the state’s laws to fetuses at all stages of
pregnancy.141 The Oklahoma Supreme Court recently struck down a ballot

140. See McCullough et al., supra note 7, at 903 (noting that clinical investigator concern
about legal liability “surely counts as a legitimate self-interest”).
141. See Laura Guidry-Grimes & Elizabeth Victor, Another Roadblock to Including Women
in Research, 42 HASTINGS CTR. REPORT 49 (2012) (discussing measures struck down in several
states, including Colorado, South Dakota, California, and Mississippi).
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initiative that would have ascribed all rights and privileges to fetuses at all
stages of development because the law conflicts with U.S. Supreme Court
decisions permitting abortion prior to viability.142 The problems with such
laws include interference with legalized abortion, with the use of certain
types of birth control, and potentially with a pregnant woman’s participation
in clinical research, if the research presented any potential for harm to the
fetus.143 The tragic situation of the recent Texas case in which a pregnant
and brain dead woman was being maintained on “life support” in an effort
to allow her fetus to develop sufficiently to be viable illustrates the lengths to
which state legislatures will go in the name of protecting fetuses.144 In a
similar vein, the FDA in recent years has been influenced by the political
interference of cultural and religious conservative groups in its evaluation of
certain regulated drugs. As a recent example, last year, a federal court
struck down the non-science-based compromise agreement to sell the socalled morning after pill, Plan B, over the counter for girls aged 15 and over
who could present valid identification for proof of age.145 In this type of
regulatory culture, it is unsurprising that the relevant regulatory bodies, IRBs,
and clinical researchers may hesitate to initiate research which may result in
injury to a mother or her fetus, making the initiation of RTCs particularly
difficult. IRBs and their members may also fear tort liability under these
circumstances.
These concerns, together with the genuine challenges of informed
consent, study design, and characterization of risk and benefit, make the
prospect of clinical research with pregnant women quite daunting. In this
culture, there remains a virtually zero risk tolerance for potential injury to the

142. See In re Initiative Pet. No. 395, 286 P.3d 637 (Okla. 2012) (finding that the
measure violated Planned Parenthood v. Casey, 505 U.S. 833 (1992)).
143. See Guidry-Grimes & Victor, supra note 141, at 49 (suggesting that researchers in
states with personhood legislation will be reluctant to enroll pregnant women and women of
childbearing age for fear of liability).
144. See Nomaan Merchant, Pregnant, Brain-Dead Woman’s Husband Sues Hospital, CHI.
SUN-TIMES, Jan. 14, 2014, http://www.suntimes.com/news/nation/24958547-418/pregnant
-brain-dead-womans-husband-sues-hospital.html (outlining the case of Marlise Munoz,
discussing the Texas Advance Directives Act which states that, “A person may not withdraw or
withhold life-sustaining treatment under this subchapter from a pregnant patient” and
questioning this provision’s applicability to a person who is legally dead).
145. See Brent Kendall & Mark H. Anderson, Restricted Access to Plan B Pill Overturned,
WALL ST. J., Apr. 9, 2013, http://online.wsj.com/news/articles/SB10001424127887324600
704578404393383162004 (describing the opinion from Judge Edward Korman for the
Eastern District of New York which concluded that the age restrictions for over the counter
access to Plan B were “arbitrary and unreasonable”). See also Tummino v. Hamburg, 936 F.
Supp. 2d 198 (E.D.N.Y. 2013) (discussing the political pressure brought to bear on the FDA
and the Bush and Obama administrations with regard to the over-the-counter sales of Plan B).
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fetus. Nevertheless, the need for more and better quality data about the
safety and efficacy of prescription drugs for pregnant women and fetuses is
sorely needed. We should not allow fear of liability or pressure from various
political or religious groups to interfere with progress in clinical research that
promises to improve the safety of prescription drugs for many pregnant
women and their fetuses.
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